Citigroup Increases IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $29.00

IDEAYA Biosciences (NASDAQ:IDYA – Get Rating) had its price target raised by investment analysts at Citigroup from $26.00 to $29.00 in a research note issued on Friday, The Fly reports. Citigroup’s price target points to a potential upside of 93.46% from the company’s current price.

A number of other equities research analysts have also recently issued reports on IDYA. Oppenheimer upped their target price on IDEAYA Biosciences from $22.00 to $26.00 in a research report on Monday, January 23rd. Guggenheim reissued a “buy” rating and issued a $32.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, March 8th. Capital One Financial initiated coverage on IDEAYA Biosciences in a research report on Wednesday, December 28th. They issued an “overweight” rating and a $29.00 price objective for the company. Wedbush increased their price objective on IDEAYA Biosciences to $30.00 in a research report on Wednesday, December 14th. Finally, Robert W. Baird upped their target price on IDEAYA Biosciences from $18.00 to $24.00 and gave the company an “outperform” rating in a research note on Friday, November 18th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $28.22.

IDEAYA Biosciences Trading Down 4.9 %

NASDAQ IDYA opened at $14.99 on Friday. The stock’s 50-day moving average price is $17.20 and its two-hundred day moving average price is $16.13. The company has a market cap of $725.32 million, a PE ratio of -10.78 and a beta of 0.89. IDEAYA Biosciences has a 1 year low of $8.14 and a 1 year high of $19.14.

Institutional Trading of IDEAYA Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Logos Global Management LP boosted its holdings in IDEAYA Biosciences by 10.3% in the third quarter. Logos Global Management LP now owns 4,135,000 shares of the company’s stock valued at $61,694,000 after acquiring an additional 385,000 shares during the last quarter. Avidity Partners Management LP boosted its holdings in IDEAYA Biosciences by 2.9% in the fourth quarter. Avidity Partners Management LP now owns 3,824,800 shares of the company’s stock valued at $69,497,000 after acquiring an additional 109,400 shares during the last quarter. BVF Inc. IL boosted its holdings in IDEAYA Biosciences by 17.9% in the third quarter. BVF Inc. IL now owns 3,294,859 shares of the company’s stock valued at $49,159,000 after acquiring an additional 500,000 shares during the last quarter. Federated Hermes Inc. boosted its holdings in IDEAYA Biosciences by 32.4% in the third quarter. Federated Hermes Inc. now owns 2,862,091 shares of the company’s stock valued at $42,702,000 after acquiring an additional 700,000 shares during the last quarter. Finally, BlackRock Inc. boosted its holdings in IDEAYA Biosciences by 2.0% in the third quarter. BlackRock Inc. now owns 2,675,556 shares of the company’s stock valued at $39,919,000 after acquiring an additional 53,268 shares during the last quarter. 94.20% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Company Profile

(Get Rating)

IDEAYA Biosciences, Inc engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.